A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women

A Randomized, Double-blind Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women

The purpose of this study is to evaluate the efficacy of hydrolyzed collagen in osteoarthritis.

Study Overview

• Status: Completed
• Conditions: Osteoarthritis; Osteoarthritis, Knee; Osteoarthritis, Hip
• Intervention / Treatment: Dietary supplement: Hydrolyzed Collagen; Other: Placebo; Dietary supplement: CalGo

Detailed Description

The current study is part of a larger project called the CalGo-project. The overall purpose of the study is to use bone meal from salmon to promote skeletal health. Specifically, the potential for hydrolyzed collagen type II derived from salmon bone meal in ameliorating pain, stiffness and function in participants diagnosed with osteoarthritis will be evaluated over a time period of 6 months. Past literature indicates that collagen derivatives may be a potential supportive strategy in people suffering from osteoarthritis. Osteoarthritis is a common but complex joint disease with significant unmet medical needs, as there are currently no disease-modifying drugs available. Osteoarthritis represents a global health burden and the only curative treatment when pain becomes unmanageable, is joint replacement.

The dimensions of pain, stiffness, and function will be evaluated using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC 3.1). Plain x-rays with Kellgren-Lawrence grading will be employed to classify the severity of osteoarthritis. 100 potential participants will be screened for eligibility. Participants who meet the eligibility criteria will be randomized in a double-blind manner to receive 10 capsules daily of hydrolyzed collagen type II (a total of 5000 mg), 10 capsules daily of salmon bone meal, or 10 capsules daily of placebo.

• Study Type: Interventional
• Enrollment (Actual): 98
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Norway
  • Oslo, Norway, 0456
    • Lovisenberg Diakonale Sykehus
  • Møre Og Romsdal
    • Kristiansund, Møre Og Romsdal, Norway, 6508
      • Kristiansund Hospital
    • Ålesund, Møre Og Romsdal, Norway, 6005
      • Hofseth Biocare ASA

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Characteristic joint pain indicating osteoarthritis (OA) in the hip(s) or knee(s).
• A radiologically and clinically verified diagnosis of mild to moderate OA graded 1-3 on a Kellgren-Lawrence (KL) grading scale in affected hips or knees.
• Age 18-70 years.
• Familiar with the Norwegian language, both in writing and orally.
• Willingness to participate in the study.

Exclusion Criteria:

• A radiologically and clinically verified diagnosis of severe OA graded 4 on a KL grading scale in affected hips or knees.
• Use of drugs (and supplements) known to influence bone and joint metabolism, including Glucocorticoids, > 500 mg daily intake of elemental calcium in medication or supplement form, > 800 IU daily intake of vitamin D3, cancer therapy
• Pregnancy or breastfeeding
• Known fish allergy and history of hypersensitivity to any of the components in the interventional product.
• Other reasons which the principal investigator deems it necessary to exclude a potential participant.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Hydrolyzed Collagen type II; 10 capsules daily of hydrolyzed collagen (CH) type II is taken per orally. Each capsule contains ~500 mg of CH. Once or twice daily dosing. Duration: 6 months.	Dietary supplement: Hydrolyzed Collagen; Hydrolyzed collagen type II derived from the bone powder of Norwegian Atlantic salmon.
Placebo Comparator: Maltodextrin; 10 capsules daily of maltodextrin is taken per orally. Each capsule contains 500 mg of maltodextrin. Once or twice daily dosing. Duration: 6 months.	Other: Placebo; Pure maltodextrin.
Experimental: Unhydrolyzed Collagen type II (Salmon bone meal); 10 capsules daily of salmon bone meal enriched with vitamin D3 is taken per orally. Each capsule contains 300 mg of maltodextrin, 200 mg of salmon bone meal (10 capsules = 2000 mg salmon bone meal = 340 mg elemental calcium in the form of microcrystalline hydroxyapatite), and 4 micrograms of vitamin D3 (10 capsules = 40 micrograms of vitamin D3 = 1600 IU).	Dietary supplement: CalGo; CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and collagen type 2.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean change from Baseline in WOMAC composite score at Month 3 and Month 6.	A change in osteoarthritis symptomatology is assessed using a disease specific questionnaire (WOMAC 3.1).	Baseline, 3 Months, and 6 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean change from from Baseline on the WOMAC pain subscale at Month 3 and Month 6.	Pain is evaluated using the pain dimension of WOMAC 3.1, a disease-specific questionnaire. The pain subscale includes 5 items that assesses pain intensity. A score is produced when the value of each item is summarized. A higher score indicates worse pain.	Baseline, 3 Months, and 6 Months
Change from Baseline on an 11-point likert Global Assessment Scale at Month 3 and Month 6.	A GAS scale gives an overall picture of an individuals' self-assessed effect of treatment. The individual is asked to compare the present health status with their health status at a previous point in time. The magnitude of this difference is scored numerically. In this study, we will use GAS on a 11-point Likert rating scale ranging from "completely recovered" to "worse than ever", with 0 being "unchanged" status.	Baseline, 3 Months, and 6 Months
Change from Baseline in pain intensity on a Numerical Rating Scale at Month 3 and Month 6.	In this study, we will employ an 11-point (i.e., 0 to 10) Numerical Rating Scale as was recommended for use in chronic pain trials according to 2005 IMMPACT guidelines. 0 represents "No pain", and 10 represents "The most intense pain imaginable".	Baseline, 3 Months, and 6 Months
Change from Baseline in number of rescue medications self-administered during the study period.	Rescue medications that participants may use on an as needed basis include Paracetamol, typical NSAIDs, and analgesics containing opioids.	Baseline, 6 Months
Change from Baseline in self-assessed quality of life on the EQ-5D-3L instrument at Month 3 and Month 6.	EQ-5D-3L is a standardized instrument used to measure generic quality of life based on five distinct dimensions. EQ-5D-3L contains two parts. The first part contains five questions that the individual must answer and includes mobility (walking), self-care, usual activities, pain/discomfort, and anxiety/depression. For each item, there are three possible answers. Results are reported as a five-digit number ranging from 11111 (best health status) to 33333 (worst health status).	Baseline, 3 Months, and 6 Months
Difference in number of Adverse Events between the study groups.	Reported between the hydrolyzed collagen group and placebo group, and the CalGo group and placebo group.	3 Months, and 6 Months.

Collaborators and Investigators

• Sponsor: Hofseth Biocare ASA
• Collaborators: Møre og Romsdal Hospital Trust
• Investigators: Principal Investigator: Øystein Bjerkestrand Lian, MD, PhD, Møre og Romsdal Hospital Trust (Helse Møre og Romsdal), Kristiansund Hospital

Study record dates

Study Major Dates

• Study Start (Actual): September 22, 2021
• Primary Completion (Actual): December 27, 2023
• Study Completion (Actual): January 15, 2024

Study Registration Dates

• First Submitted: September 23, 2021
• First Submitted That Met QC Criteria: October 4, 2021
• First Posted (Actual): October 7, 2021

Study Record Updates

• Last Update Posted (Estimated): February 13, 2024
• Last Update Submitted That Met QC Criteria: February 12, 2024
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: osteoarthritis; pain; stiffness; knee pain; hip pain
• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee; Osteoarthritis, Hip
• Other Study ID Numbers: CALGO-ART

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No